SHANGHAI – Ascletis Inc., a Chinese biotech with deep pockets, has obtained exclusive China rights for PPI-668, an NS5A inhibitor of the hepatitis C virus (HCV), from the San Francisco-based Presidio Pharmaceuticals Inc. That candidate, in combination with a prior one licensed from Roche AG, is expected to provide Chinese patients with an interferon-free cure for HCV.